Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin vs Paclitaxel in Early-Stage HER2-Negative Breast Cancer
NCT01593020Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2012
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eribulin in breast cancer, sponsored by University of Texas MD Anderson Cancer Center. Started Aug 2012; status: completed.
02
Drugs
eribulin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01593020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01593020.